- Gyre Pharmaceuticals Receives IND Approval from China’s NMPA to Evaluate F230 for the Treatment of Pulmonary Arterial Hypertension
- Gyre Therapeutics Announces Expected Addition to the Russell 2000® and Russell 3000® Indexes
- Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
- Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
- Gyre Therapeutics Expands Board of Directors with Appointment of Rodney L. Nussbaum
- Gyre Therapeutics Presents Poster at the American Association for the Study of Liver Diseases (AASLD) Annual Liver Meeting
More ▼
Key statistics
As of last trade, Gyre Therapeutics Inc (GYRE:NAQ) traded at 10.69, 223.06% above the 52 week low of 3.31 set on Jun 09, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 10.80 |
---|---|
High | 11.06 |
Low | 10.62 |
Bid | 10.60 |
Offer | 10.72 |
Previous close | 10.84 |
Average volume | 88.03k |
---|---|
Shares outstanding | 85.51m |
Free float | 15.62m |
P/E (TTM) | -- |
Market cap | 971.39m USD |
EPS (TTM) | -1.88 USD |
Data delayed at least 15 minutes, as of Jun 06 2024 18:34 BST.
More ▼